CDK10抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human small cell malignant tumors (lymphoma) tissue lysate, Primary antibody: P07184(CDK10 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P07184(CDK10 Antibody) at dilution 1/75. (Original magnification: ×200)    

  
  

The cyclin-dependent kinase 10 (CDK10) is a member of the CDK family, which plays critical roles in regulating cell cycle progression, transcriptional elongation, and signal transduction. Unlike other CDKs involved in direct cell cycle control, CDK10 forms a complex with cyclin M (CNNM) and is implicated in modulating the Ras/MAPK signaling pathway and transcriptional regulation via interactions with the ETS2 transcription factor. Dysregulation of CDK10 has been linked to various cancers, including breast, colon, and liver cancers, where its loss or mutation may promote tumorigenesis by disrupting cell proliferation, apoptosis, and metastasis-related pathways.

CDK10 antibodies are essential tools for studying its expression, localization, and function in both normal and diseased states. These antibodies enable detection of CDK10 protein levels via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding in the identification of its downregulation or aberrant activity in cancer samples. Additionally, they facilitate research into CDK10's role in developmental processes and its potential as a therapeutic target or biomarker. Recent studies also explore CDK10's involvement in resistance to certain anticancer therapies, highlighting its broader clinical relevance. Validation of CDK10 antibodies remains crucial to ensure specificity, given sequence homologies among CDK family members.